IDH2 and acute myeloid leukemia: In a phase 3 randomized study from the BEAT AML Master trial, older patients with IDH2-mutant R/R AML were randomized to ENA or conventional care [85]; patients in the ENA arm had a doubling of event-free survival (EFS) and significant improvements in CR/CRi/CRp rates and hematologic response.